Alzheimer's & Dementia

Atomoxetine not linked to lower Alzheimer’s risk in older adults

An analysis of 70,225 Medicare beneficiaries aged 66 or older compared people who started the drug with nonstarters over five and 10 years.

Paper by Adam P. Bress, Yizhe Xu, Zachary A. Marcum, +3 more authorsAladdin H. Shadyab · Intermountain Healthcare Department of Population Health Sciences Divisions of Health System Innovation and Research and Biostatistics Spencer Fox-Eccles School
Figure 1. Open in figure viewer Weighted cumulative incidence curve of incident Alzheimer's disease (AD) and AD-free death by treatment group among Medicare beneficiaries.
Open the figure at full size
Figure 1. Open in figure viewer Weighted cumulative incidence curve of incident Alzheimer's disease (AD) and AD-free death by treatment group among Medicare…Open in figure viewer Weighted cumulative incidence curve of incident Alzheimer's disease (AD) and AD-free death by treatment group among Medicare beneficiaries.Bress et al., CC BY-NC-ND

Our read

Populations
Studied:
Cohort study of 70,225 older Medicare beneficiaries, against atomoxetine non-initiators
What changed:
Alzheimer's risk was similar in atomoxetine initiators and non-initiators at 5-year follow-up (risk ratio 1.10)
The catch:
Baseline cognitive status and mental illness severity were unmeasured potential confounders
In the record:
One of 9 papers on atomoxetine on record: 3 with results in people, 3 in animals.

Editor of record: Boris Djordjevic · AgingResearch.News

Follow @agingbrief

Among 70,225 US Medicare beneficiaries aged 66 or older, starting atomoxetine was not associated with lower Alzheimer’s disease risk over five or 10 years. The non-concurrent prospective study used existing insurance records to mimic a hypothetical randomized trial. It compared people who started atomoxetine with those who did not. Some people entered more than once, producing 70,367 study entries; 59.5% involved women.

The estimated five-year difference in Alzheimer’s risk was zero, with a range of likely values that included no difference. Participants had no previous diagnosis of mild cognitive impairment, Alzheimer’s disease or related dementias. Among people with depression, starting atomoxetine was associated with lower five-year Alzheimer’s risk. That association weakened at 10 years.

Why it matters

Alzheimer’s prevention is a proposed use for atomoxetine. The authors said its possible role among older people with depression warrants further study.

Caveats

The authors note that 87% discontinued atomoxetine within one year, limiting assessment of sustained use over several years. The results may not extend to younger people or Medicare Advantage enrollees.

From the paper

Result

The 5-year risk of AD was similar in atomoxetine initiators and non-initiators (RR, 1.10; 95% CI, 0.93 to 1.29; RD, 0.00; 95% CI, 0.00 to 0.01) …

Results, 3.2 Association of atomoxetine initiation with AD

Limitation

Dementia outcomes were identified using claims-based algorithms and may be subject to misclassification, including delayed or incomplete ascertainment.

4 DISCUSSION

Quoted word for word from the full text on alz-journals.onlinelibrary.wiley.com.

Comments

Be the first to comment.

The paper

Atomoxetine and risk of Alzheimer's disease in older adults

Adam P. Bress, Yizhe Xu, Zachary A. Marcum, +3 more authorsAladdin H. Shadyab

Intermountain Healthcare Department of Population Health Sciences Divisions of Health System Innovation and Research and Biostatistics Spencer Fox-Eccles School; Herbert Wertheim School of Public Health and Human Longevity Science University of California San Diego La Jolla California USA

Alzheimer's & Dementia, Nov 16, 2026, Open access, CC BY-NC-ND

doi.org/10.1002/trc2.70345